Activation of the Protein C System During Cardiopulmonary Bypass With and Without Aprotinin
|
|
- Jared McDowell
- 5 years ago
- Views:
Transcription
1 Activation of the Protein C System During Cardiopulmonary Bypass With and Without Aprotinin Ron G. H. Speekenbrink, MD, Rogier M. Bertina, PhD, Francisco España, PhD, Charles R. H. Wildevuur, MD, PhD, and Leon Eijsman, MD, PhD Department of Thoracic Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands Background. The protein C system is important in the regulation of hemostasis. We studied its behavior during coronary artery bypass grafting procedures with and without aprotinin treatment using assays sensitive for activation of the protein C system. Methods. In a prospective, double-blind, randomized study of 48 patients we investigated the levels of antigen to proteins C and S and of the complexes between activated protein C with its two major plasma inhibitors, protein C inhibitor and 1 -antitrypsin in patients treated with placebo (n 17), low-dose (n 15), and high-dose (n 16) aprotinin during elective coronary artery bypass grafting. Results. The levels of proteins C and S showed a rapid decrease after heparinization, decreased greatly after start of cardiopulmonary bypass, and remained stable during cardiopulmonary bypass. Activated protein C inhibitor complexes were markedly elevated at the start of the procedure. Activated protein C 1 -antitrypsin decreased greatly after the start of cardiopulmonary bypass and remained stable during cardiopulmonary bypass. A significant peak was observed at the intensive care unit. Activated protein C protein C inhibitor levels showed a peak after heparinization in accordance with the accelerating effect of heparin on the complex formation but decreased thereafter. Treatment with aprotinin did not notably alter any of the measured patterns. Conclusions. In this study no evidence was found for increased activation of the protein C system during coronary artery bypass grafting. Administration of aprotinin did not result in different patterns of activation of the protein C system. (Ann Thorac Surg 1998;66: ) 1998 by The Society of Thoracic Surgeons Despite its central role in the regulation of blood coagulation, little is known about the behavior of the protein C system during cardiopulmonary bypass (CPB). The protein C system primarily consists of the plasma factors proteins C and S and the endotheliumbound thrombomodulin. Thrombomodulin present on the endothelium binds circulating thrombin to form a complex that catalyzes the conversion of protein C to activated protein C (APC). Activated protein C, together with its cofactor protein S, inhibits further thrombin generation by inactivating factors Va and VIIIa. In addition to this anticoagulant effect, APC can neutralize the plasminogen activator inhibitors PAI-1 and PAI-3 and enhance fibrinolysis. Congenital deficiencies of protein C, its cofactor protein S, and a resistance of factor Va to inactivation by APC due to a mutation in factor V result in a hypercoagulable state and are associated with an increased risk of venous thrombosis and pulmonary embolism [1]. In previous studies, significant decreases in the levels Accepted for publication June 4, Address reprint requests to Dr Speekenbrink, Department of Thoracic Surgery, Onze Lieve Vrouwe Gasthuis, P.O. Box 95500, 1090 HM Amsterdam, the Netherlands. of antigens of proteins C and S during CPB have been observed [2, 3]. This was interpreted as the result of activation of the protein C system during CPB, although markers for the activation of this system were not measured. However, the observed changes in protein C and S levels can also be explained by other mechanisms like binding of the proteins to the extracorporeal circuit [4]. To be able to distinguish these possibilities we have supplemented our array of assays in this study with recently developed assays that measure the complexes formed by APC with its natural inhibitors protein C inhibitor (PCI) and 1 -antitrypsin ( 1 AT). Because of the relatively long half-lives of these complexes, 40 and 140 minutes, respectively, they are considered to be sensitive markers for APC generation [5]. The protease inhibitor aprotinin is widely used as an adjunct in blood-saving programs [6, 7]. In vitro studies have shown that aprotinin is a competitive inhibitor of APC similar to the natural inhibitors PCI and 1 - antitrypsin [8]. Therefore, aprotinin might contribute to the inactivation of APC in vivo. In this double-blind placebo-controlled study we investigated the behavior of the protein C system during coronary artery bypass grafting with and without the use of aprotinin by The Society of Thoracic Surgeons /98/$19.00 Published by Elsevier Science Inc PII S (98)
2 Ann Thorac Surg SPEEKENBRINK ET AL 1998;66: PROTEIN C DURING CPB 1999 Patients and Methods The study was performed at the Onze Lieve Vrouwe Gasthuis in Amsterdam, The Netherlands, and the study protocol was approved by the hospitals medical ethical committee. Written informed consent was obtained from all patients. Forty-eight patients scheduled for elective primary coronary bypass grafting were randomly selected. These patients were part of a larger group of patients in which the clinical effects of low- and high-dose aprotinin were studied. The results of the latter study have been published previously [9]. Anesthesia consisted of premedication with lorazepam, induction with sufentanyl, pancuronium bromide, and etomidate or propofol, and was maintained with a continuous infusion of sufentanyl. Routinely, an infusion of dopamine and nitroglycerin was started at the termination of CPB. The extracorporeal circuit contained either a William- Harvey HF 5400 (Bard, Tustin, CA) or an Avecor Ultrox I (Avecor, Plymouth, MN) oxygenator primed with 2,000 ml of Ringer s lactate, 200 ml of 20% human albumin, 100 ml of 20% mannitol, 50 ml of 8% sodium bicarbonate, 50 mg of heparin, and 2 g of cefamandole. Before cannulation, bovine heparin (3 mg/kg) was administered. Additional doses of 50 mg were given after every hour of extracorporeal circulation irrespective of the cecite-activated clotting time, because aprotinin interferes with this measurement. Heparin was neutralized with protamine sulfate in a 1:1 ratio with the initial heparin dose. Additional dosage of protamine was guided by repeat activated clotting times after the residual volume in the extracorporeal circuit had been returned to the patient. Flow ranges were between 2.0 and 2.4 L m 2 min 1 during moderate hypothermia (28 to 32 C). Cardioplegia was achieved with ice-cold crystalloid cardioplegia infused in the ascending aorta after clamping. The study medication was provided by Bayer Leverkusen A.G., Germany, in coded bottles. The code was kept by the manufacturer. All patients received 12 bottles containing 50 ml. Four bottles marked pump were added to the pump prime, four bottles marked infus were administered as a loading dose in 30 minutes after induction of anesthesia, and four bottles marked infus were given as a maintenance dose at a rate of one bottle per hour. The bottles contained either placebo (placebo group) or 500,000 KIU (70 mg) aprotinin (high-dose group). In the low-dose group only the pump bottles contained 500,000 KIU (70 mg) aprotinin and the infus bottles contained placebo. Blood Sampling and Assays Blood samples were drawn from a central venous line or the extracorporeal circuit after induction of anesthesia, after administration of heparin, 5 minutes and 30 minutes after onset of extracorporeal circulation, before and after release of the aortic cross-clamp, after administration of protamine sulfate, and 2 and 4 hours after arrival at the intensive care unit. The samples were collected in tubes containing sodium citrate (final concentration, 1.05 mmol/l). For the measurement of APC inhibitor complexes blood was collected in 5-mL tubes containing 0.2 ml of a medium composed of g of ethylenediaminetetraacetic acid, g of benzamidine, and 0.25 g of soybean trypsin inhibitor per 100 ml. The samples were centrifuged at 3,000 rpm for 10 minutes at 4 C, and the plasma obtained was stored in aliquots at 20 C. Protein C antigen was measured by enzyme-linked immunosorbent assay using a monoclonal antibody (C12) as coating and rabbit antiprotein C immunoglobulin G, conjugated to horseradish peroxidase as the second antibody. Protein S antigen was measured by polyclonal enzyme-linked immunosorbent assay as previously described [10]. Activated protein C PCI complex and APC- 1 -antitrypsin complex concentrations were measured with sandwich enzyme-linked immunosorbent assay techniques according to previously described methods [11, 12]. In all results the ratio between the initial hematocrit and the hematocrit at the sampling point was used to correct data for hemodilution. Statistics Graphs depict mean values standard error. Categorical data were analyzed with the Kruskal-Wallis statistic. Continuous data were analyzed with analysis of variance. The Bonferroni-Holm procedure was used to correct for the multiple comparison artifacts. For laboratory assays differences between groups were analyzed with analysis of variance for repeated measures. All analyses were performed with SPSS software (SPSS Inc, Chicago, IL). Results Patient Data A total of 48 patients entered the study (17 patients in the placebo group, 15 in the 2 million KIU [280 mg] group and 16 in the 6 million KIU [840 mg] group). The demographic data and baseline coagulation studies of the groups are shown in Table 1. The differences between the groups were not significant. The perioperative course in the patients was uneventful. No major complications occurred. Protein C Antigen The concentrations of protein C in the plasma samples were measured in an enzyme-linked immunosorbent assay using a coating antibody (C12) directed at the active site of protein C. This antibody does not recognize APC inhibitor complexes. The results are shown in Figure 1. The course of protein C antigen levels was essentially the same in the three groups, with a rapid decrease after heparinization and start of CPB. This decrease was significant in the placebo and high-dose group (p and p 0.006, respectively). In the placebo group the levels seemed to increase slowly during and after CPB to reach almost the preoperative level, but in the aprotinin-
3 2000 SPEEKENBRINK ET AL Ann Thorac Surg PROTEIN C DURING CPB 1998;66: Table 1. Patient Data Variables Placebo Low-Dose High-Dose Number Age (y) Sex (% male) BSA (m 2 ) Preoperative ASA 12/17 10/15 12/16 Until preoperative day Distal anastomoses LIMA used (%) Perfusion time (min) Cross-clamp time (min) APTT (s) PTT (s) Bleeding time (s) Chest tube drainage (ml) hours postoperative Transfusion (U) Packed cells Fresh frozen plasma Data are expressed as the mean the standard deviation. No significant differences between the groups. APTT activated partial thromboplastin time; ASA acetylsalicylic acid; BSA body surface area; LIMA left internal mammary artery; PTT prothrombin time. treated patients the levels remained unchanged during this period. However, analysis of variance for repeated measures did not show a significant difference in the course of the protein C levels between the groups. Total Protein S The course of the levels of protein S (Fig 2) resembled the course seen for protein C; a sharp decrease after heparinization and start of CPB, which was significant in the Fig 2. Concentrations of protein S antigen corrected for hemodilution. The levels changed significantly in all groups (p ), but did not differ between groups. Within group differences and abbreviations are marked as in Fig 1. placebo and high-dose group (p ) and almost no change during and after CPB. With analysis of variance for repeated measures a significant difference in the course of protein S levels between the groups could not be demonstrated. Activated Protein C Protein C Inhibitor The levels of APC PCI were far above normal ( ng/ml) at the first sampling point. The levels of the complexes increased significantly (p 0.006) in all groups after heparinization (Fig 3), which is not surprising as heparin promotes APC PCI complex formation. The decrease after initiation of CPB was significant in the placebo and low-dose groups, but not in the high-dose group. In the high-dose group a sharp decrease was seen after neutralization of heparin with protamine sulfate (p 0.001). The levels continued to decrease in all groups to reach low values 4 hours after arrival in the intensive care unit. Although the levels in the high-dose aprotinin group are consistently higher during CPB, analysis of Fig 1. Concentrations of protein C antigen corrected for hemodilution. The bar represents cardiopulmonary bypass (CPB) and the triangle indicates the release of the aortic cross-clamp. (Hep administration of heparin; Prot administration of protamine sulfate.) The levels changed significantly in all groups (p ), but did not differ between the groups. Significant within group changes are marked by an asterisk for the placebo group; for the low-dose group, and # for the high-dose group. Fig 3. Concentrations of activated protein C protein C inhibitor corrected for hemodilution. The levels changed significantly in all groups (p ) but did not differ between groups. Within group differences and abbreviations are marked as in Fig 1.
4 Ann Thorac Surg SPEEKENBRINK ET AL 1998;66: PROTEIN C DURING CPB 2001 Fig 4. Concentrations of activated protein C 1 -antitrypsin corrected for hemodilution. The levels changed significantly in all groups (p ) but did not differ between groups. Within group differences and abbreviations are marked as in Fig 1. variance for repeated measures did not demonstrate a significant difference between the groups. Activated Protein C 1 Antitrypsin Activated protein C 1 AT levels were far above normal (7 2 ng/ml) at the first sampling point (Fig 4) but decreased sharply after the start of CPB (p in the aprotinin-treated groups) and remained stable during the rest of CPB. At the intensive care unit an increase followed by a significant decrease (p 0.005) was seen in all groups. Analysis of variance for repeated measures did not show a significant difference between the groups. Comment This study was performed to elucidate the pattern of protein C activation during CPB with and without the use of aprotinin. Interestingly, we measured elevated levels of APC PCI (normal, ng/ml) and APC 1 AT (normal, 7 2 ng/ml) before CPB at the first sampling point (ie, after induction of anesthesia). The levels of APC 1 AT are in the range of those found in such procoagulant states as preeclampsia or hemodialysis [13]. Because we did not measure these complexes before the procedure we cannot differentiate whether the observations are typical for this patient group with atherosclerotic complications or result from the anesthetic procedures. Further studies to elucidate this finding are warranted. At the onset of CPB we found sharp decreases of protein C and S antigen levels, which persisted through the remainder of the procedure. However, the levels did remain within normal limits (75% to 125%). These findings are in accordance with the results of Tanaka and colleagues [3], but differ from those of Knöbl and associates [2]. The latter found no decrease at the onset of CPB, and only a small but significant decrease of protein C antigen after release of the aortic cross-clamp. Furthermore, free protein S was increased during the entire CPB procedure, possibly resulting from release by activated platelets [14]. On the basis of these data both investigators and their colleagues concluded that the protein C system was activated during CPB. Although all these reported decreases of protein C antigen appear to be small, about 20%, similar reductions in physiologic circumstances are associated with massive activation and result in high levels of APC. However, our results with the new APC inhibitor complex assays show the highest concentration before the operation, but they decrease rapidly at the onset of CPB independent of hemodilution. Clearly these results are not compatible with the massive production of APC that would be expected when the decrease of protein C would be the consequence of activation of the system. This might indicate that the decrease of proteins C and S is not attributable to activation but could be explained by binding of these proteins to the extracorporeal circuit. The generation of thrombin and the activation of the protein C system are closely coupled through the formation of thrombin thrombomodulin complexes on the endothelium. Therefore, the patterns for thrombin generation and activation of the protein C system would be expected to be very similar. In previous studies we and other investigators have found a typical pattern with increased thrombin generation at the onset of CPB and after release of the aortic cross-clamp [9, 15]. Our present data, however, show no indication for increased activation of protein C surrounding these events. An explanation for this discrepancy could be that the thrombin measured after the initiation of cardiopulmonary bypass and cross-clamp release was generated outside the blood vessels where there is no coupling with protein C activation. Tabuchi and colleagues [16] have shown that pericardial blood contains high concentrations of thrombin antithrombin complexes and low heparin levels. Recirculation of this cardiotomy suction blood resulted in increased levels of thrombin antithrombin complexes in the systemic blood. Because cardiotomy suction is used mostly after the start of bypass and release of the aortic cross-clamp, this mechanism could very well be responsible for the observed discrepancy between thrombin generation and protein C activation. In vitro studies have shown that aprotinin is an inhibitor of APC with a mechanism of action similar to that of PCI and 1 AT [8]. This inhibitory effect of aprotinin has been implicated in the pathogenesis of perioperative thromboembolic complications [17, 18]. Westaby and colleagues [19] specifically warned of the combination of deep hypothermic circulatory arrest and the use of aprotinin as their retrospective series demonstrated an increased incidence of diffuse intravascular coagulation in aprotinin-treated patients. The combination of low flow or circulatory arrest combined with inhibition of plasmin and the protein C system by aprotinin was thought to be responsible for this effect. Other clinical studies [20 22] have both confirmed and rejected the findings of Westaby and colleagues [19]. Although the affinity of aprotinin for APC is not as strong as that of PCI and 1 AT, in vitro studies have demonstrated that the affinity of aprotinin for APC is increased by heparin to approach
5 2002 SPEEKENBRINK ET AL Ann Thorac Surg PROTEIN C DURING CPB 1998;66: that of kallikrein [9]. Moreover, high concentrations of aprotinin are used during CPB. On the other hand, numerous other proteases present during CPB (eg, plasmin), compete for binding sites on aprotinin. Nevertheless, aprotinin treatment might still result in additional inhibition of APC. This inhibition would result in a shift of APC from PCI and 1 AT to aprotinin and therefore, lower concentrations of APC PCI and APC 1 AT would be expected in the aprotinin-treated patients. Because the high-dose regimen uses not only three times the amount of aprotinin as the low-dose regimen, but also it is administered during the entire procedure, these changes would be most notable in the high-dose group. Our present results are contrary to these predicted findings. We found very similar patterns of APC 1 AT complexes with no significant difference between the groups. The patterns for APC PCI complexes were practically identical in the placebo and low-dose groups. There appears to be a different, albeit not significant, pattern in the high-dose group with persistently higher levels of APC PCI during CPB in contrast to the expected lower levels. The course and especially the abrupt decrease after protamine administration suggest a role for heparin. Heparin is known to enhance APC PCI complex formation and this effect is responsible for the peak we observed in all groups after heparinization. There was, however, no significant difference between the groups in the initial and maintenance doses of heparin used during the procedure (data not shown). Alternatively, the higher levels of APC PCI in the high-dose group could be the result of a heparin-sparing effect of aprotinin resulting in APC PCI complex formation. This, however, is unlikely because of the identical patterns we found in the lowdose aprotinin and placebo groups. It should be emphasized that we have used an indirect way to demonstrate the absence of an inhibitory effect of aprotinin on APC in vivo. Definitive evidence can only be provided by an assay specific for APC aprotinin complexes. Unfortunately this assay is not available. In conclusion, the results from this study do not provide evidence for activation of the protein C system during CPB. Moreover, our results do not show an influence of aprotinin administration on the activation of the protein C system during CPB. We are indebted to J. J. P. Nauta, MSc, for his statistical advice. References 1. Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med 1986;314: Knöbl PN, Zilla M, Muller MM, et al. The protein C system in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987:94: Tanaka K, Wada K, Morimoto T, et al. The role of the protein C thrombomodulin system in physiologic anticoagulation during cardiopulmonary bypass. Trans Am Soc Artif Intern Organs 1989;35: Lyman DJ, Knutson K, McNeil B, Shibatani K. The effects of chemical structure and surface properties of synthetic polymers on the coagulation of blood. IV: The relation between polymer morphology and protein adsorption. Trans Am Soc Artif Intern Organs 1975;21: España F, Gruber A, Heeb MJ, Hanson SR, Harker LA, Griffin JH. In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood 1991;8: Schönberger JPAM, Bredee JJ, van Oeveren W, et al. Preoperative therapy of low-dose aspirin in internal mammary artery bypass with and without low-dose aprotinin (2 million KIU). J Thorac Cardiovasc Surg 1993;106: Speekenbrink RGH, Vonk ABA, Wildevuur CRH, Eijsman L. Hemostatic efficacy of dipyridamol, tranexamic acid and aprotinin in coronary bypass grafting. Ann Thorac Surg 1995;59: España F, Estelles A, Griffin JH, Aznar J, Gilabert J. Aprotinin (Trasylol) is a competitive inhibitor of activated protein C. Thromb Res 1989;56: Speekenbrink RGH, Wildevuur CRH, Sturk A, Eijsman L. Low-dose and high-dose aprotinin improve hemostasis in coronary surgery. J Thorac Cardiovasc Surg 1996;112: Deutz Terlouw PP, Ballering L, van Wijngaarden A, Bertina RM. Two ELISAs for measurement of protein S, and their use in the laboratory diagnosis of protein S deficiency. Clin Chim Acta 1990;186: España F, Griffin JH. Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISAs. Thromb Res 1989;55: España F, Vicente V, Tabernero D, Scharrer I, Griffin JH. Determination of plasma protein C inhibitor and of two activated protein C inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990;59: España F, Gilabert J, Vicente V, et al. Activated protein C: 1 -antitrypsin (APC: 1 -AT) complex as a marker for in vitro diagnosis of prethrombotic states. Thromb Res 1992;62: Schwarz HP, Heeb MJ, Wencel-Drake JD, Griffin JH. Identification and quantification of protein S in human platelets. Blood 1985;66: Boisclair MD, Lane DA, Philippou H, et al. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F 1 2. Thromb Haemost 1993;70: Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106: Van Oeveren W, van Oeveren B, Wildevuur CRH. Anticoagulation policy during use of aprotinin in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992;104: Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993; 55: Westaby S, Forni A, Dunning J, et al. Aprotinin and bleeding in profoundly hypothermic perfusion. Eur J Cardiothorac Surg 1994;8: Sundt TM, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993;55: Okita Y, Takamoto S, Ando M, Morota T, Yamaki F, Kawashima Y. Is use of aprotinin safe with deep hypothermic circulatory arrest in aortic surgery? Investigations on blood coagulation. Circulation 1996;94(suppl 2): Goldstein DJ, DeRosa CM, Mogero LB, et al. Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest. J Thorac Cardiovasc Surg 1995;110:
Intra-operative Effects of Cardiac Surgery Influence on Post-operative care. Richard A Perryman
Intra-operative Effects of Cardiac Surgery Influence on Post-operative care Richard A Perryman Intra-operative Effects of Cardiac Surgery Cardiopulmonary Bypass Hypothermia Cannulation events Myocardial
More informationI bypass (CPB) circuit causes platelet damage and impairment
Aprotinin Reduces Intraoperative and Postoperative Blood Loss in Membrane Oxygenator Cardiopulmonary Bypass Marcel P. Harder, MD, Leon Eijsman, MD, Klaas J. Roozendaal, MD, Willem van Oeveren, PhD, and
More informationCardiopulmonary Support and Physiology
Cardiopulmonary Support and Physiology Hemostatic effects of tranexamic acid in elective thoracic aortic surgery: A prospective, randomized, double-blind, placebo-controlled study Valter Casati, MD a Luca
More informationComparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery
Butler Journal of Undergraduate Research Volume 2 Article 24 2016 Comparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery Lisa K. LeCleir Butler University, lisa.lecleir@gmail.com
More informationPostoperative Aprotinin: Effect on Blood Loss and Transfusion Requirements in Cardiac Operations
Postoperative Aprotinin: Effect on Blood Loss and Transfusion Requirements in Cardiac Operations Serta~ (~i~ek, MD, Ufuk Demirkili~, MD, Erkan Kuralay, MD, Ertugrul Ozal, MD, and Harun Tatar, MD Department
More informationThursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III
REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels
More informationHow can ROTEM testing help you in cardiac surgery?
How can ROTEM testing help you in cardiac surgery? Complicated bleeding situations can appear intra and post operatively. They can be life-threatening and always require immediate action. A fast differential
More informationTransfusion and Blood Conservation
Transfusion and Blood Conservation Kenneth G. Shann, CCP Assistant Director, Perfusion Services Senior Advisor, Performance Improvement Department of Cardiovascular and Thoracic Surgery Montefiore Medical
More informationCABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin
CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used
More informationCLOTTING AND FIBRINOLYTIC DISTURBANCE DURING LUNG TRANSPLANTATION: EFFECT OF LOW-DOSE APROTININ
CLOTTING AND FIBRINOLYTIC DISTURBANCE DURING LUNG TRANSPLANTATION: EFFECT OF LOW-DOSE APROTININ Y. J. Gu, MD, PhD J. de Haan, PhD U. P. M. Brenken, MD, PhD W. J. de Boer, MD Jm. Prop, MD, PhD W. van Oeveren,
More informationCardiothoracic Fellow Expectations Division of Cardiac Anesthesia, Beth Israel Deaconess Medical Center
The fellowship in Cardiothoracic Anesthesia at the Beth Israel Deaconess Medical Center is intended to provide the foundation for a career as either an academic cardiothoracic anesthesiologist or clinical
More informationWithin coronary patients, those who are affected by
The Role of Antithrombin III in the Perioperative Management of the Patient With Unstable Angina Marco Rossi, MD, Lorenzo Martinelli, MD, Sergio Storti, MD, Michele Corrado, MD, Roberto Marra, MD Carmelita
More informationGoing on Bypass. What happens before, during and after CPB. Perfusion Dept. Royal Children s Hospital Melbourne, Australia
Going on Bypass What happens before, during and after CPB. Perfusion Dept. Royal Children s Hospital Melbourne, Australia Circulation Brain Liver Kidneys Viscera Muscle Skin IVC, SVC Pump Lungs R.A. L.V.
More informationDisseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS
به نام خدا Disseminated Intravascular Coagulation M.Bahmanpour MD Assistant professor IUMS Algorithm for Diagnosis of DIC DIC Score factor score Presence of known underlying disorder No= 0 yes=2 Coagolation
More informationTechnique for Routine Use of Heparin Bonded Circuits with a Reduced Anticoagulation Protocol
Original Article Technique for Routine Use of Heparin Bonded Circuits with a Reduced Anticoagulation Protocol Paul J. O Gara, BS, CCP; Patrick R. Treanor, CCP; Kevin J. Lilly, CCP; Richard F. Crowley,
More informationHemodialysis (HD) has improved the prospects of. Sonoclot Analysis in Cardiac Surgery in Dialysis- Dependent Patients
CARDIOVASCULAR Sonoclot Analysis in Cardiac Surgery in Dialysis- Dependent Patients Toshihiko Shibata, MD, PhD, Yasuyuki Sasaki, MD, PhD, Koji Hattori, MD, PhD, Hidekazu Hirai, MD, Mitsuharu Hosono, MD,
More informationRetransfusion of Suctioned Blood During Cardiopulmonary Bypass Impairs Hemostasis
Retransfusion of Suctioned Blood During Cardiopulmonary Bypass Impairs Hemostasis Jacob de Haan, Msc, Piet W. Boonstra, MD, PhD, Stefan H. J. Monnink, MD, Tjark Ebels, MD, PhD, and Willem van Oeveren,
More informationThe Efficacy of Low Prime Volume Completely Closed Cardiopulmonary Bypass in Coronary Artery Revascularization
Original Article The Efficacy of Low Prime Volume Completely Closed Cardiopulmonary Bypass in Coronary Artery Revascularization Hideaki Takai, MD, Kiyoyuki Eishi, MD, Shiro Yamachika, MD, Shiro Hazama,
More informationGoals and Objectives. Assessment Methods/Tools
CA-2 CARDIOTHORACIC ANESTHESIA ROTATION Medical Center Fairview (UMMC) Rotation Site Director: Drs. Ioanna Apostolidou & Douglas Koehntop Rotation Duration: 6 weeks Introduction: The overall goal of the
More informationIntraoperative application of Cytosorb in cardiac surgery
Intraoperative application of Cytosorb in cardiac surgery Dr. Carolyn Weber Heart Center of the University of Cologne Dept. of Cardiothoracic Surgery Cologne, Germany SIRS & Cardiopulmonary Bypass (CPB)
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationConventional CABG Or On Pump Beating Heart: A Difference In Myocardial Injury?
Conventional CABG Or On Pump Beating Heart: A Difference In Myocardial Injury? Kornelis J. Koopmans Medical Center Leeuwarden Leeuwarden, The Netherlands I have no disclosures Disclosures Different techniques
More informationAugust, 2015 STATE MEDICAL FACULTY OF WEST BENGAL. Preliminary Examinations for Diploma in Perfusion Technology : DPfT. Paper I ANATOMY & PHYSIOLOGY
August, 2015 STATE MEDICAL FACULTY OF WEST BENGAL Paper I ANATOMY & PHYSIOLOGY Time 3 hours Full Marks 80 Group A Q-1) Write the correct Answer: 10x1 = 10 i) The posterior descending artery is branch of
More informationCardiac anaesthesia. Simon May
Cardiac anaesthesia Simon May Contents Cardiac: Principles of peri-operative management for cardiac surgery Cardiopulmonary bypass, cardioplegia and off pump cardiac surgery Cardiac disease and its implications
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationBlood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy
Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference
More informationCCAS CPB Workshop Curriculum Outline Perfusion: What you might not know
CCAS CPB Workshop Curriculum Outline Perfusion: What you might not know Scott Lawson, CCP Carrie Striker, CCP Disclosure: Nothing to disclose Objectives: * Demonstrate how the cardiopulmonary bypass machine
More informationIncreased postoperative blood loss after cardiac operations
Efficacy of Aprotinin, Epsilon Aminocaproic Acid, or Combination in Cyanotic Heart Disease Sandeep Chauhan, MD, Bisoi Akshay Kumar, MCh, Beeraka Heramba Rao, MD, Marigaddi Sanjeeva Rao, MCh, Bharat Dubey,
More informationSt George Hospital Renal Department Guideline: INTERNAL ONLY ANTICOAGULATION - COMMENCEMENT OF HAEMODIALYSIS
ANTICOAGULATION - COMMENCEMENT OF HAEMODIALYSIS Summary Aim: To prevent clotting of the extracorporeal circuit during haemodialysis If there are no contraindications, heparin can be used. In the first
More informationECMO vs. CPB for Intraoperative Support: How do you Choose?
ECMO vs. CPB for Intraoperative Support: How do you Choose? Shaf Keshavjee MD MSc FRCSC FACS Director, Toronto Lung Transplant Program Surgeon-in-Chief, University Health Network James Wallace McCutcheon
More informationBlood Management of the Cardiac Patient in the Postoperative Period
Blood Management of the Cardiac Patient in the Postoperative Period Al Stammers, MSA, CCP, Eric Tesdahl, PhD Andy Stasko MS, CCP, RRT, Linda Mongero, BS, CCP, Sam Weinstein, MD, MBA Goal To examine the
More informationOPCABG for Full Myocardial Revascularisation How we do it
OPCABG for Full Myocardial Revascularisation How we do it 28 th SHA Conferance Dr.Farouk Oueida Head of Cardiac Surgery Dept. SBCC-Dammam KSA The Less Invasive CABG Full Revascularisation Full Sternotomy
More informationAlternative Anticoagulation during Cardiovascular Procedures in Pediatric Patients with Heparin-Induced Thrombocytopenia
The Journal of ExtraCorporeal Technology Alternative Anticoagulation during Cardiovascular Procedures in Pediatric Patients with Heparin-Induced Thrombocytopenia I. Ricardo Argueta-Morales, MD; Monica
More informationFemoral Versus Aortic Cannulation for Surgery of Chronic Ascending Aortic Aneurysm
Femoral Versus Aortic Cannulation for Surgery of Chronic Ascending Aortic Aneurysm Fitsum Lakew, MD, Piotr Pasek, MD, Michael Zacher, MD, Anno Diegeler, MD, and Paul P. Urbanski, MD Department of Cardiovascular
More informationEffects of Prostacyclin Infusion on Platelet Activation and Postoperative Blood Loss in Coronary Bypass
Effects of Prostacyclin Infusion on Platelet Activation and Postoperative Blood Loss in Coronary Bypass Claes Aren, M.D., Kurt Feddersen, M.D., and Kjell Ridegran, M.D. ABSTRACT The effects of infusion
More informationStability of prothrombin time and activated partial thromboplastin time tests under different storage conditions
Clinica Chimica Acta 300 (2000) 13 21 www.elsevier.com/ locate/ clinchim Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions L.V. Rao *, A.O.
More informationThe increasing use of normothermic cardiopulmonary
A Prospective, Randomized Study of Cardiopulmonary Bypass Temperature and Blood Transfusion Paul E. Stensrud, MD, Gregory A. Nuttall, MD, Maria A. de Castro, MD, Martin D. Abel, MD, Mark H. Ereth, MD,
More informationHemostasis Alterations in Patients With Acute Aortic Dissection
ADULT CARDIAC Hemostasis Alterations in Patients With Acute Aortic Dissection Domenico Paparella, MD, Crescenzia Rotunno, BSc, Pietro Guida, PhD, Pietro Giorgio Malvindi, MD, Giuseppe Scrascia, MD, Micaela
More informationCurrent status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest
Anesthesiology Clin N Am 21 (2003) 527 551 Current status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest Jeffrey A. Green, MD*, Bruce D. Spiess, MD Department
More informationLow Dose versus High Dose Heparinization during Post Cardiotomy ECMO: A Case Control Study Disclosures Introduction
Low Dose versus High Dose Heparinization during Post Cardiotomy ECMO: A Case Control Study Vanessa Arnold, BS Mindy M Blackwell, MS, CCP Perfusion Technology Program College of Health Sciences Rush University
More informationHemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands
Hemostasis and thrombosis in patients with liver disease Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands Importance of the liver in hemostasis Synthesis of Coagulation factors Fibrinolytic proteins
More informationClinical Implications of the Impact of Serum Tissue Factor Levels after Trauma
Clinical Implications of the Impact of Serum Tissue Factor Levels after Trauma Ian E. Brown, MD, PhD, and Joseph M. Galante MD, FACS Formatted: Font: 16 pt, Bold Formatted: Centered Formatted: Font: Bold
More informationSolution for cardiac perfusion in viaflex plastic container
CARDIOPLEGIA SOLUTION A Solution for cardiac perfusion in viaflex plastic container DESCRIPTION Cardioplegia Solution A is a sterile, non-pyrogenic solution in a Viaflex bag. It is used to induce cardiac
More informationPerfusion for Repair of Aneurysms of the Transverse Aortic Arch
technique This new section is open for technicians to explore the unusual, the difficult, the innovative methods by which perfusion meets the challenge of the hour and produces the ultimate goal - a life
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationSafety of Heparin-Coated Circuits in Primates During Deep Hypothermic Cardiopulmonary Bypass
Original Article Safety of Heparin-Coated Circuits in Primates During Deep Hypothermic Cardiopulmonary Bypass Joseph j. Sistino, MPA, CCP, Robert E. Michler, MD, Linda B. Mongero, BS, CCP, Arthur Schwartz,
More informationThe systemic inflammatory response that occurs to a
Inflammatory Mediators in Adults Undergoing Cardiopulmonary Bypass: Comparison of Centrifugal and Roller Pumps Saeed Ashraf, FRCS(C/Th), John Butler, FRCS(I), Yi Tian, MCh, Dahlia Cowan, BSc, Simon Lintin,
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More informationAprotinin Dosing: How Much Is Enough?
The Journal of The American Society of Extra-Corporeal Technology Aprotinin Dosing: How Much Is Enough? Kevin S. Niimi, MPS, CCP St. Louis Children s Hospital, St. Louis, Missouri Abstract: Coagulopathy
More informationRisk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease
Risk Factor Evaluation for Thrombosis and Bleeding in Pediatric Patients with Heart Disease Kristen Nelson, MD Johns Hopkins University Director, Pediatric Cardiac Critical Care Why Does it Matter? Pediatric
More informationEvaluation of Biocompatible Cardiopulmonary Bypass Circuit Use During Pediatric Open Heart Surgery
The Journal of The American Society of Extra-Corporeal Technology Evaluation of Biocompatible Cardiopulmonary Bypass Circuit Use During Pediatric Open Heart Surgery Joseph Deptula, MPS, CCP; Kimberly Glogowski,
More informationUniversity of Groningen. Impaired Organ Perfusion Morariu, Aurora
University of Groningen Impaired Organ Perfusion Morariu, Aurora IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationHematologic Disorders. Assistant professor of anesthesia
Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationOPCAB IS NOT BETTER THAN CONVENTIONAL CABG
OPCAB IS NOT BETTER THAN CONVENTIONAL CABG Harold L. Lazar, M.D. Harold L. Lazar, M.D. Professor of Cardiothoracic Surgery Boston Medical Center and the Boston University School of Medicine Boston, MA
More informationCardiac surgery is associated with a high incidence of
Retrograde Autologous Priming of the Cardiopulmonary Bypass Circuit Reduces Blood Transfusion After Coronary Artery Surgery Subramaniam Balachandran, FRCA, Michael H. Cross, FRCA, Sivagnanam Karthikeyan,
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationRequirement in Coronary Bypass Surgery
Blood Loss and Bank Blood Requirement in Coronary Bypass Surgery Thomas Yeh, Jr., Larry Shelton, C.C.P., and Thomas J. Yeh, M.D. ABSTRACT With the use of nonblood prime and refinement in perfusion and
More informationAre Anti- Fibrinolytic Drugs the Magic Bullets for Perioperative Hemostasis?
Are Anti- Fibrinolytic Drugs the Magic Bullets for Perioperative Hemostasis? Daniela Filipescu, MD. PhD. Assoc. Prof. of Anesthesia & Intensive Care Carol Davila University Emergency Institute of Cardiovascular
More informationReprinted in the IVIS website with the permission of the ACVP and ASVCP
Proceedings of the Annual Meeting of the American College of Veterinary Pathologists and American Society for Veterinary Clinical Pathology - Tucson, Arizona 2006 - Reprinted in the IVIS website with the
More informationEMSS17: Bleeding patients course material
EMSS17: Bleeding patients course material Introduction During the bleeding patients workshop at the Emergency Medicine Summer School 2017 (EMSS17) you will learn how to assess and treat bleeding patients
More informationWhen Should I Use Tranexamic Acid for Children? Dr Andrea Kelleher Consultant Adult and Paediatric Cardiac Anaesthetist
When Should I Use Tranexamic Acid for Children? Dr Andrea Kelleher Consultant Adult and Paediatric Cardiac Anaesthetist When? When a drug is licenced for (the proposed) use When its use is supported by
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/37409 holds various files of this Leiden University dissertation Author: Engbers, Marissa Title: Conventional and age-specific risk factors for venous thrombosis
More informationDISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital
DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital Disseminated intravascular coagulation (DIC) Disseminated
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationPackage leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin
Package leaflet: Information for the patient Trasylol 10,000 KIU/ml solution for injection or infusion Aprotinin Read all of this leaflet carefully before you are given this medicine because it contains
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions.
Percutaneous Coronary Intervention https://www.youtube.com/watch?v=bssqnhylvma Types of PCI Procedures Balloon Angioplasty Rotational Atherectomy Coronary Stent Balloon Inflation Rotational Atherectomy
More informationAccepted Manuscript. Perioperative renal function and thoracoabdominal aneurysm repair: Where do we go from here? Leonard N. Girardi, M.D.
Accepted Manuscript Perioperative renal function and thoracoabdominal aneurysm repair: Where do we go from here? Leonard N. Girardi, M.D. PII: S0022-5223(18)31804-X DOI: 10.1016/j.jtcvs.2018.06.057 Reference:
More informationPrimary Exam Physiology lecture 5. Haemostasis
Primary Exam Physiology lecture 5 Haemostasis Haemostasis Body s response for the prevention and cessation of bleeding. Broadly consists of: Primary Haemostasis - vascular spasm and platlet plug formation
More informationC CONFERENCIAS MAGISTRALES Vol. 36. Supl. 1 Abril-Junio 2013 pp S31-S35 Bleeding following deep hypothermia and circulatory arrest in children Emad B Mossad, MD* * Division of Pediatric Cardiovascular
More informationHOW TO PREPARE A GOOD ACCEPTED
HOW TO PREPARE A GOOD ABSTRACT AND GET IT ACCEPTED This is an interactive session; be free to interrupt and ask questions at any time during the talk! Some useful points when deciding if and where to submit
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationThinking outside of the box Perfusion management and myocardial protection strategy for a patient with sickle cell disease
Thinking outside of the box Perfusion management and myocardial protection strategy for a patient with sickle cell disease Shane Buel MS, RRT 1 Nicole Michaud MS CCP PBMT 1 Rashid Ahmad MD 2 1 Vanderbilt
More informationInteresting Cases - A Case Report: Renal Cell Carcinoma With Tumor Mass In IVC And Heart. O Wenker, L Chaloupka, R Joswiak, D Thakar, C Wood, G Walsh
ISPUB.COM The Internet Journal of Thoracic and Cardiovascular Surgery Volume 3 Number 2 Interesting Cases - A Case Report: Renal Cell Carcinoma With Tumor Mass In IVC And Heart O Wenker, L Chaloupka, R
More informationCitation for published version (APA): van den Goor, J. M. M. H. (2008). Clinical aspects of blood activation in open-heart surgery
UvA-DARE (Digital Academic Repository) Clinical aspects of blood activation in open-heart surgery van den Goor, J.M.M.H. Link to publication Citation for published version (APA): van den Goor, J. M. M.
More informationReduction of the Inflammatory Response in Patients Undergoing Minimally Invasive Coronary Artery Bypass Grafting. Patients and Methods Patients
Reduction of the Inflammatory Response in Patients Undergoing Minimally Invasive Coronary Artery Bypass Grafting Y. John Gu, MD, PhD, Massimo A. Mariani, MD, PhD, Willem van Oeveren, PhD, Jan G. Grandjean,
More informationSdO 2. p Hypothermic circulatory arrest: HCA n = 6 Continuous retrograde cerebral perfusion: retrograde cerebral perfusion: IRCP
20 3 49 55 2005 2 24 4 SdO 2 SdO 2 SdO 2 p 0.01 1999 409-3898 1110 2005 4 27 2005 4 27 JW 24 Hypothermic circulatory arrest: HCA n = 6 Continuous retrograde cerebral perfusion: n = 6 Intermittent retrograde
More informationAortic Arch/ Thoracoabdominal Aortic Replacement
Aortic Arch/ Thoracoabdominal Aortic Replacement Joseph S. Coselli, M.D. Vice Chair, Department of Surgery Professor, Chief, and Cullen Foundation Endowed Chair Division of Cardiothoracic Surgery Baylor
More informationEmergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
More informationCoagulopathy: Measuring and Management. Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine
Coagulopathy: Measuring and Management Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine No Financial Disclosures Objectives Define coagulopathy of trauma Define
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationHemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins
Hemostasis Learning objectives 14-16 Dr. Mária Dux Components: blood vessel wall thrombocytes (platelets) plasma proteins Hemostatic balance! procoagulating activity anticoagulating activity 1 Thrombocytes
More informationAprotinin Inhibits Protease-Dependent Platelet Aggregation and Thrombosis
Aprotinin Inhibits Protease-Dependent Platelet Aggregation and Thrombosis Tanveer A. Khan, MD, Cesario Bianchi, MD, PhD, Pierre Voisine, MD, Jennifer Sandmeyer, BS, Jun Feng, MD, PhD, and Frank W. Sellke,
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationUse of Bivalirudin as an Anticoagulant During Cardiopulmonary Bypass
The Journal of The American Society of Extra-Corporeal Technology Use of Bivalirudin as an Anticoagulant During Cardiopulmonary Bypass James J. Veale, CCP;* Harry M. McCarthy, CCP; George Palmer, MD; Cornelius
More informationCh. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma
Chapt. 45 Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma Inheritance of X-linked gene for Factor VIII hemophilia A Explain the
More informationPublic Assessment Report Scientific discussion. Trasylol (aprotinin) SE/H/1671/01/MR
Public Assessment Report Scientific discussion Trasylol (aprotinin) SE/H/1671/01/MR This module reflects the scientific discussion for the approval of Trasylol. The procedure was finalised on 2018-02-06.
More informationMirsad Kacila*, Katrin Schäfer, Esad Subašić, Nermir Granov, Edin Omerbašić, Faida Kučukalić, Ermina Selimović-Mujčić
& Influence of Two Different Types of Cardioplegia on Hemodilution During and After Cardiopulmonary Bypass, Postoperative Chest-Drainage Bleeding and Consumption of Donor Blood Products Mirsad Kacila*,
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationHeart transplantation is the gold standard treatment for
Organ Care System for Heart Procurement and Strategies to Reduce Primary Graft Failure After Heart Transplant Masaki Tsukashita, MD, PhD, and Yoshifumi Naka, MD, PhD Primary graft failure is a rare, but
More informationThe Treatment of Postperfusion Bleeding Using wlminocaproic Acid, Cryoprecipitate, Fresh-Frozen Plasma, and Protamine Sulfate
The Treatment of Postperfusion Bleeding Using wlminocaproic Acid, Cryoprecipitate, Fresh-Frozen Plasma, and Protamine Sulfate Cary J. Lambert, M.D., Alain J. Marengo-Rowe, M.D., James E. Leveson, Ph.D.,
More informationBLEEDING AND USE OF BLOOD PRODUCTS AFTER HEART OPERATIONS IN INFANTS
BLEEDING AND USE OF BLOOD PRODUCTS AFTER HEART OPERATIONS IN INFANTS From Children's Hospital, University of Helsinki, Finland. Received for publication March 10, 1994. Accepted for publication July 29,
More informationLeukocyte depletion has been implicated in attenuating
ORIGINAL ARTICLES: CARDIOVASCULAR Leukocyte Depletion During Cardiac Operation: A New Approach Through the Venous Bypass Circuit Y. John Gu, MD, PhD, A. J. de Vries, MD, Paulien Vos, Piet W. Boonstra,
More informationIncidence and pattern of Thrombocytopenia in cardiac surgery patients
1019 ORIGINAL ARTICLE Incidence and pattern of Thrombocytopenia in cardiac surgery patients Mohammad Hamid, Mohammad Irfan Akhtar, Hamid Iqil Naqvi, Khalid Ahsan Abstract Objective: To observe the incidence
More informationMASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE
MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE CONTENTS Definition Indications Transfusion trigger Massive transfusion protocol Complications DEFINITION Massive transfusion:
More informationHematology Review. CCRN exam. The Coagulation Cascade. The Coagulation Cascade. Components include: Intrinsic pathway Extrinsic pathway Common pathway
CCRN exam Hematology Review CCRN Review October 2013 Department of Critical Care Nursing Hematology is 2% of the exam Focus on coagulation cascade, DIC, and HIT Anatomy of the hematologic system Bone marrow
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationSELECTIVE ANTEGRADE TECHNIQUE OF CHOICE
SELECTIVE ANTEGRADE CEREBRAL PERFUSION IS THE TECHNIQUE OF CHOICE MARKO TURINA University of Zurich Zurich, Switzerland What is so special about the operation on the aortic arch? Disease process is usually
More informationUse of Recombinant Factor VIIa (NovoSeven) in Pediatric Cardiac Surgery
The Journal of ExtraCorporeal Technology Use of Recombinant Factor VIIa (NovoSeven) in Pediatric Cardiac Surgery Scott D. Niles, BA, CCP;* Harold M. Burkhart, MD;* David A. Duffey, BS, BSN, CCP;* Keri
More informationGUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS
CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA Introduction: GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS These guidelines have been developed in conjunction with the hospital Transfusion Committee.
More information